Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on May 1, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Updated corporate presentation discloses efficacy estimates and confidence intervals for reproxalap’s proposed commercial dosing trials.
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation discloses efficacy estimates and confidence intervals for reproxalap’s proposed commercial dosing trials
- FDA positions and Aldeyra interpretations on primary endpoints highlighted for dry eye disease NDA
- Endpoint disclosures may affect investor assessment of reproxalap approval probability and regulatory risk
- Corporate Overview furnished as Exhibit 99.1 for detailed estimates and FDA commentary
Item EX-99.1 · Exhibit EX-99.1
- Cash, cash equivalents, and marketable securities $70.0M as of 12/31/2026; company expects funding into 2028
- Reproxalap received an FDA complete response letter for dry eye disease, eliminating near-term approval certainty
- Type A FDA meeting expected Q2 2026 to discuss reproxalap’s rejection and potential regulatory path
- AbbVie option could provide $100M upfront, $100M approval milestone, $200M additional milestones, and U.S. 60%/40% profit sharing
- ADX-2191 Phase 3 PVRL and Phase 2/3 retinitis pigmentosa trials expected to begin H1 2026, creating key clinical catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.